245 related articles for article (PubMed ID: 28104567)
1. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis.
Abdel-Qadir H; Ethier JL; Lee DS; Thavendiranathan P; Amir E
Cancer Treat Rev; 2017 Feb; 53():120-127. PubMed ID: 28104567
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.
Thulliez M; Angoulvant D; Le Lez ML; Jonville-Bera AP; Pisella PJ; Gueyffier F; Bejan-Angoulvant T
JAMA Ophthalmol; 2014 Nov; 132(11):1317-26. PubMed ID: 25058694
[TBL] [Abstract][Full Text] [Related]
3. Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis.
Chen YC; Chen JH; Hsieh FI
J Chin Med Assoc; 2024 Jan; 87(1):48-57. PubMed ID: 37991373
[TBL] [Abstract][Full Text] [Related]
4. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
Ranpura V; Hapani S; Chuang J; Wu S
Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
[TBL] [Abstract][Full Text] [Related]
5. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer.
Faruque LI; Lin M; Battistella M; Wiebe N; Reiman T; Hemmelgarn B; Thomas C; Tonelli M
PLoS One; 2014; 9(7):e101145. PubMed ID: 24988441
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients.
Totzeck M; Mincu RI; Rassaf T
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862931
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials.
Li J; Gu J
Clin Drug Investig; 2018 Dec; 38(12):1109-1123. PubMed ID: 30327999
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S19-26. PubMed ID: 27183521
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies.
Mikačić I; Bosnar D
Drug Saf; 2016 Jun; 39(6):517-41. PubMed ID: 26951234
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients.
Totzeck M; Mincu RI; Mrotzek S; Schadendorf D; Rassaf T
Eur J Prev Cardiol; 2018 Mar; 25(5):482-494. PubMed ID: 29376753
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events.
Ewer MS; Suter TM; Lenihan DJ; Niculescu L; Breazna A; Demetri GD; Motzer RJ
Eur J Cancer; 2014 Aug; 50(12):2162-70. PubMed ID: 24930624
[TBL] [Abstract][Full Text] [Related]
12. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
Nalluri SR; Chu D; Keresztes R; Zhu X; Wu S
JAMA; 2008 Nov; 300(19):2277-85. PubMed ID: 19017914
[TBL] [Abstract][Full Text] [Related]
13. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
[TBL] [Abstract][Full Text] [Related]
14. Comparing cardiovascular adverse events in cancer patients: A meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone.
Crocetto F; Ferro M; Buonerba C; Bardi L; Dolce P; Scafuri L; Mirto BF; Verde A; Sciarra A; Barone B; Calogero A; Sagnelli C; Busetto GM; Del Giudice F; Cilio S; Sonpavde G; Di Trolio R; Della Ratta GL; Barbato G; Di Lorenzo G
Crit Rev Oncol Hematol; 2023 Aug; 188():104059. PubMed ID: 37353178
[TBL] [Abstract][Full Text] [Related]
15. Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis.
Avery RL; Gordon GM
JAMA Ophthalmol; 2016 Jan; 134(1):21-9. PubMed ID: 26513684
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.
Tassinari D; Sartori S; Papi M; Drudi F; Castellani C; Carloni F; Tombesi P; Lazzari-Agli L
Oncology; 2011; 80(5-6):350-8. PubMed ID: 21791945
[TBL] [Abstract][Full Text] [Related]
17. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients.
Hall PS; Harshman LC; Srinivas S; Witteles RM
JACC Heart Fail; 2013 Feb; 1(1):72-8. PubMed ID: 24621801
[TBL] [Abstract][Full Text] [Related]
18. Adverse events risk associated with angiogenesis inhibitors addition to therapy in ovarian cancer: a meta-analysis of randomized controlled trials.
Liang XJ; Shen J
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(12):2701-9. PubMed ID: 27383326
[TBL] [Abstract][Full Text] [Related]
19. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Choueiri TK; Schutz FA; Je Y; Rosenberg JE; Bellmunt J
J Clin Oncol; 2010 May; 28(13):2280-5. PubMed ID: 20351323
[TBL] [Abstract][Full Text] [Related]
20. Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials.
Ueta T; Noda Y; Toyama T; Yamaguchi T; Amano S
Ophthalmology; 2014 Nov; 121(11):2193-203.e1-7. PubMed ID: 25023760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
